Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation

Hongxu Xian,Yuan Liu,Alexandra Rundberg Nilsson,Raphaella Gatchalian,Timothy R Crother,Warren G Tourtellotte,Yi Zhang,German R Aleman-Muench,Gavin Lewis,Weixuan Chen,Sarah Kang,Melissa Luevanos,Dorit Trudler,Stuart A Lipton,Pejman Soroosh,John Teijaro,Juan Carlos de la Torre,Moshe Arditi,Michael Karin,Elsa Sanchez-Lopez,Timothy R. Crother,Warren G. Tourtellotte,German R. Aleman-Muench,Stuart A. Lipton

DOI: https://doi.org/10.1016/j.immuni.2021.05.004

IF: 32.4

2021-07-01

Immunity

Abstract:Acute respiratory distress syndrome (ARDS), an inflammatory condition with high mortality rates, is common in severe COVID-19, whose risk is reduced by metformin rather than other anti-diabetic medications. Detecting of inflammasome assembly in post-mortem COVID-19 lungs, we asked whether and how metformin inhibits inflammasome activation while exerting its anti-inflammatory effect. We show that metformin inhibited NLRP3 inflammasome activation and interleukin (IL)-1β production in cultured and alveolar macrophages along with inflammasome-independent IL-6 secretion, thus attenuating lipopolysaccharide (LPS)- and SARS-CoV-2-induced ARDS. By targeting electron transport chain complex 1 and independently of AMP-activated protein kinase (AMPK) or NF-κB, metformin blocked LPS-induced and ATP-dependent mitochondrial (mt) DNA synthesis and generation of oxidized mtDNA, an NLRP3 ligand. Myeloid-specific ablation of LPS-induced cytidine monophosphate kinase 2 (CMPK2), which is rate limiting for mtDNA synthesis, reduced ARDS severity without a direct effect on IL-6. Thus, inhibition of ATP and mtDNA synthesis is sufficient for ARDS amelioration.

immunology